-
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
-
ChemBase ID:
72776
-
Molecular Formular:
C16H21N3O2
-
Molecular Mass:
287.35684
-
Monoisotopic Mass:
287.16337693
-
SMILES and InChIs
SMILES:
c1c(ccc2c1c(c[nH]2)CCN(C)C)C[C@@H]1NC(=O)OC1
Canonical SMILES:
CN(CCc1c[nH]c2c1cc(C[C@H]1COC(=O)N1)cc2)C
InChI:
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
InChIKey:
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
-
Cite this record
CBID:72776 http://www.chembase.cn/molecule-72776.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
|
|
|
IUPAC Traditional name
|
|
Synonyms
|
Zomig
|
Zomigon
|
AscoTopand
|
Zomigoro
|
Zolmitriptan
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
13.002183
|
H Acceptors
|
2
|
H Donor
|
2
|
LogD (pH = 5.5)
|
-1.3495891
|
LogD (pH = 7.4)
|
-0.08771248
|
Log P
|
2.0428753
|
Molar Refractivity
|
82.4392 cm3
|
Polarizability
|
32.885002 Å3
|
Polar Surface Area
|
57.36 Å2
|
Rotatable Bonds
|
5
|
Lipinski's Rule of Five
|
true
|
PROPERTIES
PROPERTIES
Safety Information
Product Information
Bioassay(PubChem)
Storage Condition
|
-20°C
|
Show
data source
|
|
Salt Data
|
Free Base
|
Show
data source
|
|
DETAILS
DETAILS
Selleck Chemicals
Selleck Chemicals -
S1649
|
Research Area: Neurological Disease Biological Activity: Zolmitriptan(Zomig) is a selective serotonin receptor agonist. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches. Cytochrome 1A2 is likely to be the isoenzyme responsible for the metabolism of zolmitriptan. The increased exposure to zolmitriptan and 183C91 by cimetidine indicated that a reduction in the total daily recommended dose of zolmitriptan may be necessary when treating migraine patients who are taking nonspecific cytochrome P450 inhibitors or specific cytochrome 1A2 inhibitors. [1][2] |
PATENTS
PATENTS
PubChem Patent
Google Patent